The Latest Breaking News from Biogen

Biogen and Ionis discontinue ALS treatment development, emphasizing the need for continued research in neurodegenerative diseases.

Biogen stock jumped Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

Biogen stock jumped Friday after the FDA delayed its approval decision on Eli Lilly's rival Alzheimer's treatment, donanemab.

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).

Biogen's turnaround is still a "work in progress," an analyst said Tuesday as Biogen stock slumped on light fourth-quarter profit.

Because of its strategic focus on research and therapy improvements for long-term growth, Biogen (BIIB) could come under heat for the mixed outcomes of its recent acquisitions. As stakeholders anticipate the forthcoming earnings release, let's seek insights into the company's future trajectory and implications for BIIB shares. Read on….

A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday.